Imugene Ltd
Imugene Raises $37.5m to Advance Azer-Cel Clinical Trials for Refractory Lymphoma Patients
Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company will raise an initial $22.5 million from the placement of 68.2 million shares priced at $0.33 each, a 22.4% discount to […]
Imugene reports promising Azer-cel results for advanced lymphoma patients in Phase 1b trial
Imugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidate azer-cel on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Ten enrolled patients had previously undergone up to five lines of cancer treatment for the non-Hodgkin’s lymphoma, including autologous chimeric antigen receptor (CAR) T-cell therapy—all of which […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Imugene’s onCARlytics clears Phase 1 milestone in solid tumour therapy trial
Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study. Known as OASIS, the first-in-class trial combines a CD19-expressing oncolytic virus that flags solid tumours for attack by CD19-targeting therapeutics such as […]